Moffitt Cancer Center is partnering with Dicom Systems to scale digital pathology data management using the Unifier Platform, enabling standardized imaging workflows and supporting high-volume slide routing of up to 85,735 slides per day.
Roche has received CE mark approval for its Elecsys pTau217 blood test, designed to aid in Alzheimer’s disease diagnosis by detecting amyloid pathology in patients with cognitive decline.
Laboratories are leveraging established diagnostic and surveillance tools to track the Andes hantavirus outbreak linked to a cruise ship, with experts noting no evidence of widespread community transmission or efficient airborne spread.
HistoIndex has partnered with Houston Research Institute and Knowledge Research Center to expand access to AI-driven digital pathology for liver disease diagnostics in Texas and California.
Scopio Labs’ Full-Field Bone Marrow Aspirate Application has received EU IVDR certification, enabling high-throughput digital imaging at 100x resolution to support regulated hematology workflows on the X100 and X100HT platforms.
Researchers at Mass General Brigham identified 16 routine lab markers, including cholesterol and glucose, linked to PTSD’s physical effects, suggesting standard tests could aid in assessing the disorder’s multi-organ impact.
The ViaPlex 2-Color Cell Barcoding Kit uses two reactive fluorescent dyes to combine up to 15 distinct cell populations in one tube, reducing reagent use and run time.
The test allows for simultaneous detection of multiple viruses on a sample-to-answer platform designed for immunocompromised patients.
Fujirebio Europe has received CE marking for its automated Lumipulse G pTau 217 Plasma assay, designed to help identify amyloid pathology in patients with cognitive decline, according to the company.
AOA Dx presented data at AACR 2026 supporting its AKRIVIS GD Test System, a multi-omic, blood-based assay for early ovarian cancer detection in symptomatic women, reporting an AUC of 0.92 in clinical controls.
New research indicates that standard and modified two-tiered testing algorithms fail to detect infection in up to 78% of patients during the early stages of the disease.
Foundation Medicine and Bristol Myers Squibb have expanded their partnership to develop an NGS-based companion diagnostic for identifying homozygous MTAP deletions, supporting targeted therapy development in precision oncology.
The cobas liat system delivers PCR results in 15 minutes, detecting and differentiating between three Bordetella pathogens including whooping cough.
A rapid urine test identified effective UTI antibiotics in an average of 5.85 hours, matching standard lab accuracy in a University of Reading study published in the Journal of Antimicrobial Chemotherapy.